( Investigational Drug Being Pursued for ...)Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod),Health

GLASGOW, Scotland, May 31, 2007 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI) announced today the presentation of new analysis of data from prior clinical trials of ancrod and updates on the clinical development of their investigational drug, Viprinex (ancrod), for the treatment of acute ischemic stroke at the 16th annual European Stroke Congress in Glasgow, Scotland in the United Kingdom. Viprinex is a defibrinogenating agent derived from the venom of the Malayan pit viper.

"The ancrod data presented this week in Glasgow draws positive conclusions that support a new dosing regimen for ancrod and revised inclusion/exclusion criteria for the current clinical trials," said David Sherman, MD, University of Texas Health Science Center at San Antonio. "The reanalysis enables us to see that ancrod may be safe and effective when administered to patients within six hours of stroke onset. With so few treatments currently available to stroke patients, we look forward to the results of the international phase 3 trials. We hope the phase 3 results provide evidence of definitive safety and efficacy of ancrod in ischemic stroke in the six-hour time window."

    Viprinex(TM)-related sessions at the 2007 European Stroke Congress are:

    -- Poster Session II P 29: Ancrod in a Six Hour Time Window? Evidence For

       and Against Efficacy  by D.G.Sherman University of Texas Health Science

       Center at San Antonio, USA Thursday,  31 May 2007 13:00 to 14:00 GMT

    -- Ongoing Trials Abstract #19: Ancrod Stroke Program (ASP): Two Phase 3

       International, Multi-Center, Randomized, Double-Blind,

       Placebo-Controlled Trials of Ancrod in Acute Ischaemic Stroke by David

       E. Levy, MD (Neurobiological Technologies)

NTI is moving forward with two international, randomized, double-blind, placeb
'"/>